Table 4.
Cytoplasmic and membranous expression of the proteins in angiogenic versus non-angiogenic non-small cell lung cancers (NSCLCs)
| Protein | Intensity percentage score (IPS) of protein expression | P value | Tumour type with higher expression | |
|---|---|---|---|---|
| Angiogenic tumours | Non-angiogenic tumours | |||
| HIF1 | 6.22 ± 0.33 | 6.00 ± 0.48 | 0.87 | – |
| HIF2 | 0.00 ± 0.00 | 0.00 ± 0.00 | Not applicable | – |
| CA9 cytoplasm | 2.38 ± 0.16 | 3.50 ± 0.23 | <0.001 | Non-angiogenic |
| CA9 membrane | 4.00 ± 0.40 | 3.30 ± 0.88 | 0.62 | – |
| VEGFA | 8.83 ± 0.35 | 7.38 ± 0.78 | 0.07 | – |
| TYMP | 3.20 ± 0.54 | 2.21 ± 0.32 | 0.28 | – |
| KDR | 94.56 ± 1.64 | 97.80 ± 1.54 | >0.05 | – |
| KDRp34 | 10.40 ± 0.30 | 10.55 ± 0.62 | 0.71 | – |
| FIH | 9.10 ± 0.32 | 10.00 ± 0.47 | 0.22 | – |
| PHD1 | 3.74 ± 0.27 | 4.20 ± 0.48 | 0.47 | – |
| PHD2 | 3.50 ± 0.30 | 2.46 ± 0.53 | 0.02 | Angiogenic |
| PHD3 | 2.70 ± 0.09 | 3.38 ± 0.17 | <0.001 | Non-angiogenic |
| DLL4vessels | 2.34 ± 0.10 | 1.53 ± 0.09 | <0.001 | Angiogenic |
| TSP stroma | 16.98 ± 2.75 | 2.00 ± 1.74 | <0.001 | Angiogenic |
| CXCR4 | 2.47 ± 0.20 | 2.34 ± 0.31 | 0.92 | |
| EPHB2 | 7.78 ± 0.27 | 9.06 ± 0.33 | <0.01 | Non-angiogenic |
| EPBH3 cytoplasm | 159.3 ± 8.84 | 202.20 ± 9.95 | <0.01 | Non-angiogenic |
| EPBH3 membrane | 23.83 ± 7.23 | 86.51 ± 12.78 | <0.001 | Non-angiogenic |
| EPHB4 | 7.82 ± 0.26 | 7.40 ± 0.38 | 0.57 | – |
| SOD1 | 4.36 ± 0.45 | 9.39 ± 4.22 | 0.27 | – |
| BCL2 | 1.05 ± 0.25 | 0.68 ± 0.35 | 0.54 | – |
| FOS | 8.05 ± 0.37 | 5.31 ± 0.55 | <0.001 | Angiogenic |
| EGFR | 203.40 ± 10.79 | 166.30 ± 25.74 | 0.33 | – |
| EGF | 18.90 ± 3.03 | 14.44 ± 4.15 | 0.72 | – |
| FGF | 9.20 ± 0.42 | 9.72 ± 0.71 | 0.74 | – |
| BNIP3 | 6.08 ± 0.36 | 5.92 ± 0.82 | 0.88 | – |
| P53 | 0.28 ± 0.12 | 2.28 ± 0.56 | <0.001 | Non-angiogenic |
| PI3 | 4.62 ± 0.36 | 4.92 ± 0.61 | 0.51 | – |
| SP1 | 3.70 ± 0.37 | 3.38 ± 0.55 | 0.86 | – |
| STAT3 | 8.78 ± 0.39 | 7.11 ± 0.79 | 0.03 | Angiogenic |
| LON | 102.50 ± 11.20 | 134.20 ± 17.10 | 0.18 | – |
| MEF2D cytoplasm | 50.11 ± 4.16 | 65.67 ± 9.66 | 0.25 | – |
| MEF2Dmembrane | 60.00 ± 7.12 | 67.50 ± 12.67 | 0.47 | – |
| JMY | 1.84 ± 0.18 | 2.42 ± 0.31 | 0.05 | Non-angiogenic |
| TRAP1 | 4.22 ± 0.28 | 5.48 ± 0.31 | <0.01 | Non-angiogenic |
| GST cytoplasm | 236.20 ± 7.16 | 249.80 ± 11.40 | 0.23 | – |
| GSTmembrane | 28.44 ± 5.52 | 69.38 ± 14.03 | <0.01 | Non-angiogenic |
| NCAM | 0.40 ± 0.09 | 3.92 ± 0.07 | <0.001 | Non-angiogenic |
| CHGA | 0.08 ± 0.04 | 0.27 ± 0.14 | >0.05 | – |
| SYP | 0.12 ± 0.05 | 0.44 ± 0.15 | >0.05 | – |
All data are presented as mean ± standard error
HIF hypoxia-inducible factor; CA9 carbonic anhydrase 9; VEGFA vascular endothelial growth factor A; TYMP thymidine phosphorylase; KDR vascular endothelial growth factor receptor 2; KDRp34 vascular endothelial growth factor p34; FIH factor-inhibiting HIF; PHD prolyl hydroxylase dehydrogenase; DLL4 Delta-like 4; TSP1 thymidine phosphorylase 1; CXCR4 chemokine (C-X-C motif) receptor 4; EPH ephrin; SOD1 superoxide dismutase 1; BCL2 B cell lymphoma 2; FOS FBJ murine osteosarcoma viral oncogene homolog; EGF epidermal growth factor; EGFR epidermal growth factor receptor; BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3; PI3 peptidase inhibitor 3; SP1 Sp1 transcription factor; STAT3 signal transducer and activator of transcription 3; LON Lon protease; MEF2D myocyte enhancer factor 2D; JMY junction-mediating and regulatory protein, p53 cofactor; TRAP1 TNF receptor-associated protein 1; GST glutathione S-transferase; NCAM neural cell adhesion molecule; CHGA chromogranin A; SYP synaptophysin
– Indicates equal expression